Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Belsomra. Every FDA application for this active ingredient: 1 branded and 1 generic.
As of Nov 16, 2026, FDA lists 2 applications for Suvorexant (sold as Belsomra), first approved Aug 13, 2014, with 1 new use approved and 1 published complete response letter.
First approved: Aug 13, 2014
Applications: 2
New uses approved: 1
Complete response letters: 1
Medicare spending, 2025: $153M
First approved in Japan: Sep 26, 2014
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Suvorexant for Treatment of AUD and PTSDAlcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD) · Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA